Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms

Viruses

Volumn 5, Issue 3, 2013, Pages 981-997

  Gallay, Philippe A ^a   Ptak, Roger G ^b   Bobardt, Michael D ^a   Dumont, Jean Maurice ^c   Vuagniaux, Grégoire ^c   Rosenwirth, Brigitte ^d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c Medizinische Universitaet Wien ^*

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Alisporivir; Cyclophilin inhibitors; Cyclosporines; DEB025; HIV capsid; HIV retroviruses; Natural resistance

Indexed keywords

ALISPORIVIR; AMINO ACID; ASPARAGINE; CAPSID PROTEIN; CYCLOPHILIN A; DEB 025; GLUTAMINE; HISTIDINE; ISOLEUCINE; ISOMERASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; PROTEIN MODIFICATION; PROTEIN POLYMORPHISM; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CAPSID; CAPSID PROTEINS; CYCLOSPORINE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POLYMORPHISM, GENETIC;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 84875518763     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v5030981     Document Type: Article

References (76)

1. Fischer, G.; Bang, H.; Mech, C. Determination of enzymatic catalysis for the cis-transisomerization of peptide binding in proline-containing peptides. Biomed. Biochim. Acta 1984, 43, 1101-1111.
2. Snyder, S.H.; Sabatini, D.M. Immunophilins and the nervous system. Nat. Med. 1995, 1, 32-37.
3. Franke, E.K.; Yuan, H.E.; Luban, J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994, 372, 359-362.
4. Rosenwirth, B.; Billich, A.; Steinkasserer, A.; Hammerschmid, F.; Peichl, P.; Göttlinger, H.; Traber, R.; Wenger, R. Cyclophilin A as a novel target in anti-HIV-I chemotherapy. Int. Antivir. News 1995, 3, 62-63.
5. Thali, M.; Bukovsky, A.; Kondo, E.; Rosenwirth, B.; Walsh, C.T.; Sodroski, J.; Gottlinger, H.G., Functional association of cyclophilin A with HIV-1 virions. Nature 1994, 372, 363-365.
6. Chatterji, U.; Bobardt, M.; Selvarajah, S.; Yang, F.; Tang, H.; Sakamoto, N.; Vuagniaux, G.; Parkinson, T.; Gallay, P. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. 2009, 284, 16998-17005.
7. Coelmont, L.; Hanoulle, X.; Chatterji, U.; Berger, C.; Snoeck, J.; Bobardt, M.; Lim, P.; Vliegen, I.; Paeshuyse, J.; Vuagniaux, G.; Vandamme, A.M.; Bartenschlager, R.; Gallay, P.; Lippens, G.; Neyts, J. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One 2010, 5, e13687.
8. Kaul, A.; Stauffer, S.; Berger, C.; Pertel, T.; Schmitt, J.; Kallis, S.; Lopez, M.Z.; Lohmann, V.; Luban, J.; Bartenschlager, R. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 2009, 5, e1000546.
9. Liu, Z.; Yang, F.; Robotham, J.M.; Tang, H. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J. Virol. 2009, 83, 6554-6565.
10. Bukovsky, A.A.; Weimann, A.; Accola, M.A.; Gottlinger, H.G. Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 10943-10948.
11. Gamble, T.R.; Vajdos, F.F.; Yoo, S.; Worthylake, D.K.; Houseweart, M.; Sundquist, W.I.; Hill, C.P. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 1996, 87, 1285-1294.
12. Luban, J.; Bossolt, K.L.; Franke, E.K.; Kalpana, G.V.; Goff, S.P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993, 73, 1067-1078.
13. Billich, A.; Hammerschmid, F.; Peichl, P.; Wenger, R.; Zenke, G.; Quesniaux, V.; Rosenwirth, B. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J. Virol. 1995, 69, 2451-2461.
14. Braaten, D.; Franke, E.K.; Luban, J. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J. Virol. 1996, 70, 3551-3560.
15. Mlynar, E.; Bevec, D.; Billich, A.; Rosenwirth, B.; Steinkasserer, A. The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells. J. Gen. Virol. 1997, 78, 825-835.
16. Watashi, K.; Shimotohno, K. Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible anti-viral target. Drug. Target Insights 2007, 2, 9-18.
17. Yang, F.; Robotham, J.M.; Nelson, H.B.; Irsigler, A.; Kenworthy, R.; Tang, H. Cyclophilin A is an essential cofactor for Hepatitis C virus infection and the principal mediator of cyclosporine A resistance in vitro. J. Virol. 2008, 82, 5269-5278.
18. Dreyfuss, M.; Harri, H.; Hoffmann, H.; Kobel, H.; Pache, W.; Tscherter, H. Cyclosporin A and C. New Metabolites from Trichoderma ploysporum. Eur. J. Appl. Microbiol. 1976, 3, 125-133.
19. Handschumacher, R.E.; Harding, M.W.; Rice, J.; Drugge, R.J.; Speicher, D.W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984, 226, 544-547.
20. Ruegger, A.; Kuhn, M.; Lichti, H.; Loosli, H.R.; Huguenin, R.; Quiquerez, C.; von Wartburg, A. Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity. Helv. Chim. Acta 1976, 59, 1075-1092.
21. Borel, J.F.; Di Padova, F.; Mason, J.; Quesniaux, V.; Ryffel, B.; Wenger, R. Pharmacology of cyclosporine (Sandimmune). Pharmacol. Rev. 1989, 41, 239-242.
22. Baumann, G.; Zenke, G.; Wenger, R.; Hiestand, P.; Quesniaux, V.; Andersen, E.; Schreier, M.H. Molecular mechanisms of immunosuppression. J. Autoimmun. 1992, 5, 67-72.
23. Wenger, R.M.; Payne, T.G.; Schreier, M.H. Cyclosporine: Chemistry Structure-Activity Relationships and Mode of Action. Berger, W.R.; Flueckiger, H.G.; Koeppe, K.T.; Holmes, C.E.; Mountford, E.L.; Nickoloff, T.G.; Payne, M.H.; Schreier, I.C.P.; Smith, R.; Wenger, M. Progress in Clinical Biochemistry and Medicine, Vol. 3. Vii+191p. Springer-Verlag New York, Inc.: New York, N.Y., USA; Berlin, West Germany. Illus. Isbn 0-387-16249-6; Isbn 3-540-16249-6. 1986, 0, 157-191.
24. Huai, Q.; Kim, H.Y.; Liu, Y.; Zhao, Y.; Mondragon, A.; Liu, J.O.; Ke, H. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 12037-12042.
25. Jin, L.; Harrison, S.C. Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13522-13526.
26. Quesniaux, V.F.; Schreier, M.H.; Wenger, R.M.; Hiestand, P.C.; Harding, M.W.; Van Regenmortel, M.H. Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity. Eur. J. Immunol. 1987, 17, 1359-1365.
27. Weber, C.; Wider, G.; von Freyberg, B.; Traber, R.; Braun, W.; Widmer, H.; Wuthrich, K. The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution. Biochemistry 1991, 30, 6563-6574.
28. Rosenwirth, B.; Billich, A.; Datema, R.; Donatsch, P.; Hammerschmid, F.; Harrison, R.; Hiestand, P.; Jaksche, H.; Mayer, P.; Peichl, P.; Quesniaux, V.; Schatz, F.; Schuurman, H.-J.; Traber, R.; Wenger, R.; Wolff, B.; Zenke, G.; Zurini, M. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrobial. Agents Chemother. 1994, 38, 1763-1772.
29. Bartz, S.R.; Hohenwalter, E.; Hu, M.K.; Rich, D.H.; Malkovsky, M. Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc. Natl. Acad. Sci. U.S.A. 1995, 92(12), 5381-5385.
30. Ishii, N.; Watashi, K.; Hishiki, T.; Goto, K.; Inoue, D.; Hijikata, M.; Wakita, T.; Kato, N.; Shimotohno, K. Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol. 2006, 80, 4510-4520.
31. Ma, S.; Boerner, J.E.; TiongYip, C.; Weidmann, B.; Ryder, N.S.; Cooreman, M.P.; Lin, K. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob. Agents Chemother. 2006, 50, 2976-2982.
32. Nakagawa, M.; Sakamoto, N.; Tanabe, Y.; Koyama, T.; Itsui, Y.; Takeda, Y.; Chen, C.H.; Kakinuma, S.; Oooka, S.; Maekawa, S.; Enomoto, N.; Watanabe, M. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005, 129, 1031-1041.
33. Traber, R.; Kobel, H.; Loosli, H.R.; Senn, H.; Rosenwirth, B.; Lawen, A., [Melle4] cyclosporin, a novel natural cylosporin with anti-HIV activity. Antivir. Chem. Chemother. 1994, 5, 331-339.
34. Nakagawa, M.; Sakamoto, N.; Enomoto, N.; Tanabe, Y.; Kanazawa, N.; Koyama, T.; Kurosaki, M.; Maekawa, S.; Yamashiro, T.; Chen, C.H.; Itsui, Y.; Kakinuma, S.; Watanabe, M. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem. Biophys. Res. Commun 2004, 313, 42-47.
35. Lawitz, E.; Godofsky, E.; Rouzier, R.; Marbury, T.; Nguyen, T.; Ke, J.; Huang, M.; Praestgaard, J.; Serra, D.; Evans, T.G. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral. Res. 2011, 89, 238-245.
36. Hubler, F.; Ruckle, T.; Patiny, L.; Muamba, T.; Guichou, J.F.; Mutter, M.; Wenger, R. Synthetic routes to NEtXaa4-cyclosporin A derivates as potential anti-HIV drugs. Tetrahedron Letters 2000, 41, 7193-7196.
37. Wenger, R.M. Cyclosporine and analogues--isolation and synthesis--mechanism of action and structural requirements for pharmacological activity. Fortschr. Chem. Org. Naturst. 1986, 50, 123-136.
38. Wenger, R.; Mutter, M.; Ruckle, T. Novel cyclosporin with improved activity profile. WO 00/01715, 2000.
39. Coelmont, L.; Kaptein, S.; Paeshuyse, J.; Vliegen, I.; Dumont, J.M.; Vuagniaux, G.; Neyts, J. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob. Agents Chemother. 2009, 53, 967-976.
40. Paeshuyse, J.; Kaul, A.; De Clercq, E.; Rosenwirth, B.; Dumont, J.M.; Scalfaro, P.; Bartenschlager, R.; Neyts, J. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006, 43, 761-770.
41. Ptak, R.G.; Gallay, P.A.; Jochmans, D.; Halestrap, A.P.; Ruegg, U.T.; Pallansch, L.A.; Bobardt, M.D.; de Bethune, M.P.; Neyts, J.; De Clercq, E.; Dumont, J.M.; Scalfaro, P.; Besseghir, K.; Wenger, R.M.; Rosenwirth, B. Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent. Antimicrob. Agents Chemother. 2008, 52, 1302-1317.
42. Landrieu, I.; Hanoulle, X.; Bonachera, F.; Hamel, A.; Sibille, N.; Yin, Y.; Wieruszeski, J.M.; Horvath, D.; Wei, Q.; Vuagniaux, G.; Lippens, G. Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025. Biochemistry 2010, 49, 4679-4986.
43. Chatterji, U.; Bobardt, M.D.; Stanfield, R.; Ptak, R.G.; Pallansch, L.A.; Ward, P.A.; Jones, M.J.; Stoddart, C.A.; Scalfaro, P.; Dumont, J.M.; Besseghir, K.; Rosenwirth, B.; Gallay, P.A. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIMcyclophilin-resistant in Owl monkey cells. J. Biol. Chem. 2005, 280, 40293-40300.
44. Daelemans, D.; Dumont, J.M.; Rosenwirth, B.; De Clercq, E.; Pannecouque, C. Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle. Antiviral. Res. 2010, 85, 418-421.
45. Flisiak, R.; Dumont, J.M.; Crabbe, R. Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin. Investig. Drugs 2007, 16, 1345-1354.
46. Gallay, P.A. Cyclophilin inhibitors. Clin. Liver. Dis. 2009, 13, 403-417.
47. Flisiak, R.; Horban, A.; Gallay, P.; Bobardt, M.; Selvarajah, S.; Wiercinska-Drapalo, A.; Siwak, E.; Cielniak, I.; Higersberger, J.; Kierkus, J.; Aeschlimann, C.; Grosgurin, P.; Nicolas-Métral, V.; Dumont, J.-M.; Porchet, H.; Crabbé, R.; Scalfaro, P. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008, 47, 817-826.
48. Crabbe, R.; Vuagniaux, G.; Dumont, J.M.; Nicolas-Metral, V.; Marfurt, J.; Novaroli, L. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert. Opin. Investig. Drugs 2009, 18, 211-220.
49. Flisiak, R.; Feinman, S.V.; Jablkowski, M.; Horban, A.; Kryczka, W.; Pawlowska, M.; Heathcote, J.E.; Mazzella, G.; Vandelli, C.; Nicolas-Metral, V.; Grosgurin, P.; Liz, J.S.; Scalfaro, P.; Porchet, H.; Crabbe, R. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009, 49, 1460-1468.
50. Chatterji, U.; Lim, P.; Bobardt, M.D.; Wieland, S.; Cordek, D.G.; Vuagniaux, G.; Chisari, F.; Cameron, C.E.; Targett-Adams, P.; Parkinson, T.; Gallay, P.A. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol. 2010, 53, 50-56.
51. Chatterji, U.; Bobardt, M.; Selvarajah, S.; Yang, F.; Tang, H.; Sakamoto, N.; Vuagniaux, G.; Parkinson, T.; Gallay, P. The isomerase active site of cyclophilin a is critical for HCV replication. J. Biol. Chem. 2009, 284, 16998-17005.
52. Aberham, C.; Weber, S.; Phares, W. Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J. Virol. 1996, 70, 3536-3544.
53. Braaten, D.; Aberham, C.; Franke, E.K.; Yin, L.; Phares, W.; Luban, J. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J. Virol. 1996, 70, 5170-5176.
54. Yin, L.; Braaten, D.; Luban, J. Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J. Virol. 1998, 72, 6430-6436.
55. Berthoux, L.; Sebastian, S.; Sokolskaja, E.; Luban, J. Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc. Natl. Acad. Sci. U.S.A 2005, 102, 14849-14853.
56. Luban, J. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J. Virol. 2007, 81, 1054-1061.
57. Owens, C.M.; Song, B.; Perron, M.J.; Yang, P.C.; Stremlau, M.; Sodroski, J. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J. Virol. 2004, 78, 5423-5437.
58. Sayah, D.M.; Sokolskaja, E.; Berthoux, L.; Luban, J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 2004, 430, 569-573.
59. Stremlau, M.; Owens, C.M.; Perron, M.J.; Kiessling, M.; Autissier, P.; Sodroski, J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427, 848-853.
60. Chatterji, U.; Bobardt, M.D.; Gaskill, P.; Sheeter, D.; Fox, H.; Gallay, P.A. Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J. Biol. Chem. 2006, 281, 37025-37033.
61. Hatziioannou, T.; Perez-Caballero, D.; Cowan, S.; Bieniasz, P.D. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J. Virol. 2005, 79, 176-183.
62. Ikeda, Y.; Ylinen, L.M.; Kahar-Bador, M.; Towers, G.J. Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J. Virol. 2004, 78, 11816-11822.
63. Sayah, D.M.; Luban, J. Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection. J. Virol. 2004, 78, 12066-12070.
64. Sokolskaja, E.; Berthoux, L.; Luban, J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J. Virol. 2006, 80, 2855-2862.
65. Stremlau, M.; Song, B.; Javanbakht, H.; Perron, M.; Sodroski, J. Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology 2006, 351, 112-120.
66. Hatziioannou, T.; Cowan, S.; Goff, S.P.; Bieniasz, P.D.; Towers, G.J. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 2003, 22, 385-394.
67. Towers, G.J.; Hatziioannou, T.; Cowan, S.; Goff, S.P.; Luban, J.; Bieniasz, P.D. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 2003, 9, 1138-1143.
68. Gitti, R.K.; Lee, B.M.; Walker, J.; Summers, M.F.; Yoo, S.; Sundquist, W.I. Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science 1996, 273, 231-235.
69. Wiegers, K.; Krausslich, H.G. Differential dependence of the infectivity of HIV-1 group O isolates on the cellular protein cyclophilin A. Virology 2002, 294, 289-295.
70. Braaten, D.; Franke, E.K.; Luban, J. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J. Virol. 1996, 70, 4220-4227.
71. Matsuoka, S.; Dam, E.; Lecossier, D.; Clavel, F.; Hance, A.J. Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type. Retrovirology 2009, 6, 21.
72. Hatziioannou, T.; Cowan, S.; Von Schwedler, U.K.; Sundquist, W.I.; Bieniasz, P.D. Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J. Virol. 2004, 78, 6005-6012.
73. Tang, C.; Ndassa, Y.; Summers, M.F. Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. Nat. Struct. Biol. 2002, 9, 537-543.
74. Yang, R.; Aiken, C. A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA. J. Virol. 2007, 81, 3749-3756.
75. Fassati, A.; Goff, S.P. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J. Virol. 2001, 75, 3626-3635.
76. Gatanaga, H.; Das, D.; Suzuki, Y.; Yeh, D.D.; Hussain, K.A.; Ghosh, A.K.; Mitsuya, H. Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop. J. Biol. Chem. 2006, 281, 1241-1250.